Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our studies reveal novel insights into the regulation of NRF2 and identify DPP3 and an NRF2 transcriptional signature as potential biomarkers for breast cancer prognosis and treatment.<i>Cancer Res; 77(11); 2881-92.©2017 AACR</i>.
|
28416489 |
2017 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Collectively, our findings further support the competition model of NRF2 activation and suggest that "ETGE"-containing proteins such as DPP3 contribute to NRF2 activity in cancer.
|
23382044 |
2013 |
Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.
|
20236318 |
2010 |
Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor C/EBP-β mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells.
|
24472318 |
2014 |
Adult Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor C/EBP-β mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells.
|
24472318 |
2014 |
Adult Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.
|
20236318 |
2010 |
Childhood Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.
|
20236318 |
2010 |
Childhood Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor C/EBP-β mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells.
|
24472318 |
2014 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Our studies reveal novel insights into the regulation of NRF2 and identify DPP3 and an NRF2 transcriptional signature as potential biomarkers for breast cancer prognosis and treatment.<i>Cancer Res; 77(11); 2881-92.©2017 AACR</i>.
|
28416489 |
2017 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Collectively, our findings further support the competition model of NRF2 activation and suggest that "ETGE"-containing proteins such as DPP3 contribute to NRF2 activity in cancer.
|
23382044 |
2013 |
Glioblastoma Multiforme
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.
|
20236318 |
2010 |
Glioblastoma Multiforme
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor C/EBP-β mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells.
|
24472318 |
2014 |
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studies reveal novel insights into the regulation of NRF2 and identify DPP3 and an NRF2 transcriptional signature as potential biomarkers for breast cancer prognosis and treatment.<i></i>.
|
28416489 |
2017 |
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that DPP3 could be a new biomarker and biotarget for severe HF.
|
31472040 |
2020 |
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that DPP3 could be a new biomarker and biotarget for severe HF.
|
31472040 |
2020 |
Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Comparing the spectrum of KEAP1-interacting proteins with the genomic profile of 178 squamous cell lung carcinomas characterized by The Cancer Genome Atlas revealed amplification and mRNA overexpression of the DPP3 gene in tumors with high NRF2 activity but lacking NRF2 stabilizing mutations.
|
23382044 |
2013 |
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, absence of DPP3 augmented bone loss after estrogen withdrawal in female mice, further supporting its relevance in the framework of bone pathophysiology.
|
31295380 |
2019 |
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studies reveal novel insights into the regulation of NRF2 and identify DPP3 and an NRF2 transcriptional signature as potential biomarkers for breast cancer prognosis and treatment.<i></i>.
|
28416489 |
2017 |
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we show that DPP3 is overexpressed in breast cancer and that elevated levels of <i>DPP3</i> mRNA correlate with increased NRF2 downstream gene expression and poor prognosis, particularly for ER-positive breast cancer.
|
28416489 |
2017 |